Skip to content

Aclaris Therapeutics ACRS Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Incyte logo
IncyteINCY
$126.59M-27.9%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$0-100%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$4.41M+5.6%
Vera Therapeutics logo
Vera TherapeuticsVERA
$1.86M
Arcus Biosciences logo
Arcus BiosciencesRCUS
$119M-28.3%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$472K+27.6%

Other financials

Income statement

See full
Revenue$2.0M+37.2%
Gross profit$1.6M+68.7%
Operating income-$22.2M-22.7%
Net income-$19.8M-31.4%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$28.7M-5.6%
Total debt$2.0M-20.1%
Total equity$143.6M-0.3%
Total assets$198.7M+0.3%

Cash flow

See full
Operating cash flow-$18.1M-39.0%
CapEx$13.0K-69.8%
Free cash flow-$18.2M-38.6%

Valuation

See full
Market cap$685.75M+337%
Enterprise value$659.07M+410%
P/S82×+73.1×

Profitability

See full
Gross margin76.3%-9.7pp
Operating margin-961.9%+259pp
Net margin-832.6%+132pp
FCF margin-624.9%

Returns & leverage

See full
Return on equity-48.4%-15.4pp
Debt / equity0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aclaris Therapeutics's other non-current liabilities?
Aclaris Therapeutics (ACRS) reported other non-current liabilities of $1.42M in Q1 2026.
How has Aclaris Therapeutics's other non-current liabilities changed year-over-year?
Aclaris Therapeutics's other non-current liabilities decreased by 67.1% year-over-year, from $4.31M to $1.42M.
What is the long-term trend for Aclaris Therapeutics's other non-current liabilities?
Over 5 years (2020 to 2025), Aclaris Therapeutics's other non-current liabilities has grown at a -13.2% compound annual growth rate (CAGR), from $3.18M to $1.57M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.